Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia
- 11 May 1991
- journal article
- case report
- Published by Elsevier in The Lancet
- Vol. 337 (8750) , 1124-1125
- https://doi.org/10.1016/0140-6736(91)92788-4
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cellsEuropean Journal of Immunology, 1990
- Expression of interleukin-2 receptor beta subunit in hematopoietic malignanciesBlood, 1989
- Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.The Journal of Experimental Medicine, 1987
- The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant LymphocytesScience, 1986
- One molecule of diphtheria toxin fragment a introduced into a cell can kill the cellCell, 1978